FibroGen (FGEN) Misses Q3 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
FibroGen Reports Third Quarter 2019 Financial Results
November 11, 2019 4:01 PM ESTRoxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney WeekPlan to Submit Roxadustat U.S. NDA This Quarter
Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
Time to event endpoints using Cox model, ITT analysis NDD (OLYMPUS, ANDES, ALPS), N=4270... MoreFibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
November 8, 2019 2:10 PM ESTRoxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+
Time to event endpoints using Cox model, ITT analysis* NDD (OLYMPUS, ANDES, ALPS), N=4270*ITT analysis agreed with the FDA... More